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A b s t r a c t
Percutaneous intervention in saphenous vein grafts is associated with a high risk of distal embolisation by plaque material, ‘no
flow’ phenomenon and clinical complications such as myocardial infarction or death. According to randomised trial evi-
dence, intervention in a degenerated vein graft should be performed using an embolic protection device (EPD), since this
strategy significantly reduces periprocedural and 30 day adverse event rate. FiberNet® is a novel distal protection system with
unique characteristics of a low crossing profile (0.031’’ for vessel size 3.5–5 mm), ‘cotton wool’-like three dimensional design
and a small pore size (40 µm). The FiberNet® does not require a separate delivery sheath and self-achieves its optimal
apposition to the vessel wall; the EPD system also contains a dedicated aspiration catheter.  We present the use of FiberNet®
in a 77 year-old patient who had undergone coronary artery bypass grafting 20 years ago and currently presented with CCS
class III angina due to a significant stenosis of the saphenous vein graft to the marginal branch. The procedure involved the
use of a novel mesh-covered stent (MGuard®) designed to ‘trap’ the plaque material between the stent and the vessel wall.
It was technically successful and clinically uncomplicated, and the patient remains well six months later.
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INTRODUCTION
Atherosclerotic degenerative disease occurs in about 80% of
saphenous vein grafts (SVG) 10 to 15 years after coronary
artery bypass grafting (CABG) [1]. For this reason, 15 years
after CABG, up to 30% of patients require re-revascularisa-
tion: either reoperation or percutaneous coronary interven-
tion (PCI) [2]. SVG angioplasty is a high risk procedure but,
overall, it is associated with better long-term survival than re-
peated surgery [3]. For many years, PCI of degenerated SVG
has been associated with a risk of periprocedural myocardial
infarction (MI) or death (as a result of distal embolisation) as
high as 16.5% [4].
The introduction of embolic protection devices (EPD)
was crucial in increasing the safety of degenerated SVG-PCI.
The efficacy of EPD was first demonstrated in randomised
trials such as SAFER [4] and FIRE [5], which showed a 40%
fewer MI and deaths in the 30 day observation in compari-
son to interventions without EPDs. Current guidelines on
PCI recommend the use of distal EPDs when technically
feasible in patients undergoing SVG PCI (class I A according
to ESC, class IB according to ACC) [6, 7]. Although current
EPDs (distal-filters or the occlusion balloon, or proximal flow
blockade) significantly reduce the risk of distal embolisa-
tion, they are not fully effective in capturing embolic partic-
les (the residual embolisation risk is ≈ 10%) [8]. For this re-
ason, new generations of EPDs and stents are being develo-
ped. One new stent type dedicated to SVG-PCI combines
a stainless steel stent and a mesh cover. The cover is made
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of polyethylene terephthalate (PET) and has a mesh pore
size of 150 ¥ 180 µm. In a pilot study of SVG-PCI (mean
SVG age of 14 years), using the mesh covered stent was
associated with the risk of MI as a result of ‘no flow’ pheno-
menon in only 3.3% of patients, where EPDs were not used
due to unsuitable graft anatomy [9].
We present the use of a novel distal protection EPD
(FiberNet®) in PCI of a degenerated SVG. The procedure was
performed in a patient 20 years after CABG and involved
a mesh covered stent (MGuard®) implantation.
CASE REPORT
A 77 year-old patient with a 25-year history of MI was admitted
in 1987 to our Department because of CCS class III angina. In
1990, the patient underwent CABG with two SVGs being im-
planted: one to the left anterior descending artery (LAD) and
one to the marginal branch (Mg). Echocardiography showed
a global ejection fraction of 50% with hypokinesis of the anterior
and inferior wall. Coronary computed tomography angiography
indicated a significant stenosis of the SVG to Mg in its proximal
part, whereas the SVG to LAD was patent and appeared free of
critical lesions. Native-vessel coronary angiography showed
multivessel coronary artery disease: subtotal left main coronary
artery stenosis and proximal LAD stenosis, a significant stenosis
of circumflex artery, chronic total occlusion of first Mg and
a subtotal stenosis in the proximal segment of the unprotected
right coronary artery (RCA). Bypass graft catheter angiography
confirmed critical stenosis in the proximal part of SVG (Mg)
(Fig. 1). The SVG (LAD) was patent and it was not significantly
diseased. The patient was scheduled for a two-stage percutano-
us coronary revascularisation. In the first stage, RCA-PCI with
a drug eluting stent (Endeavor Resolute® 3.0 ¥ 15 mm) implan-
tation was performed uneventfully. Two weeks later, the patient
was admitted for the SVG (Mg)-PCI. The SVG (Mg) ostium was
intubated using a JR 4.0/6 F catheter. Due to the access anato-
my, the SVG (Mg) stenosis was crossed with BMW 0.014”
guidewire prior to introduction of the FiberNet® distal protec-
tion system. Then the device (FiberNet® 3.5–5.0 mm) was intro-
duced with BMW 0.014” guidewire serving as a ‘buddy wire’
and placed distal to the lesion. Direct implantation of a MGu-
ard® stent 4.0 ¥ 15 mm (dilatation at 10 atm, post-dilatation at
12 atm) was followed by the ‘no-flow phenomenon’ (TIMI-1) in
the treated vessel. The patient complained of severe retrosternal
pain and ECG showed profound ST depression. While the flow
was markedly impaired, several aspirations with the FiberNet®
aspiration catheter were performed (Fig. 2). This led to restora-
tion of normal (TIMI-3) flow in the SVG (Mg), while the open
FiberNet® filter was still positioned distal to the treated lesion.
The retrosternal pain resolved and the embolic protection devi-
ce was removed. Final angiography showed a normal antegrade
flow in the SVG (Mg) and in the marginal branch, and an optimal
stent apposition (Fig. 3). There was macroscopic evidence of gross
debris in the FiberNet® filter and in the aspirate. Myocardial ne-
crosis markers remained normal (cardiac troponin I 0.06 ng/mL,
CK 51 U/L, CK-MB 18 U/L). Six months later, the patient rema-
ins free of angina.
DISCUSSION
The use of conventional EPDs in SVG-PCI leads to a signifi-
cant reduction of PCI-associated major adverse events (9.4%
vs 16.5%, p = 0.004) [4]. No major clinical outcome diffe-
rences were found between various protection systems [8].
However, both proximal and distal current EPDs have im-
portant limitations. For instance, proximal lesion location (as
in the presented case, Fig. 1) precludes the use of a proximal
EPD. Flow cessation with proximal or distal occlusion per se
Figure 1. Critical stenosis of saphenous vein graft (arrow)
implanted to the marginal branch
Figure 2. Aspiration with the dedicated FiberNet® aspiration
catheter (circle)
www.kardiologiapolska.pl
1425The use of a novel type of distal protection system (FiberNet®) in the percutaneous management of saphenous vein graft disease
induces ischaemia and significantly limits the target lesion/
/vessel visualisation which can affect appropriate stent posi-
tioning. However, proximal or distal balloon occlusion devi-
ces allow effective aspiration of even small debris. Distal fil-
ters allow maintained flow during the PCI but require a suita-
ble landing zone; at least a 30 mm long atherosclerosis-free
segment [8]. The currently used filters have a pore size of 80–
–140 µm [8] that still permits embolisation with debris frag-
ments below the pore size. Importantly, in more than one in
four degenerated SVGs, no current protection system can be
applied for anatomical reasons [8]. Since the complication
rate of current EPD-protected SVG-PCI remains significant
(ª 10%), new protection systems and dedicated stent types
are being developed. The novel embolic protection system
FiberNet® was designed to combine the advantages of the
currently used embolic protection devices. The filter is made
of PET fibers with a unique three-dimensional design. The
FiberNet® does not impair the antegrade blood flow during
PCI and it captures embolic particles as small as 40 µm.
Importantly, the FiberNet® is a low profile device (crossing
profile for a 3.5–5 mm vessel size is only 0.031”). Recently,
the use of FiberNet® in carotid angioplasty (the EPIC study)
has demonstrated the high efficacy of this device (death/
/stroke/MI: 4.2% in symptomatic and 2.7% in asymptoma-
tic patients) [10].
The evidence indicates that combining the FiberNet®
embolic protection system with a mesh covered MGuard®
stent implantation may have been crucial for the safety of the
described procedure. This strategy allowed an uncomplica-
ted PCI of a degenerated, 20 year-old SVG. Despite the mo-
derate stent post-dilation pressure (12 atm), there was a fully
symptomatic ‘no flow’ syndrome (most probably due to the
high embolic load in the filter and the vessel segment proxi-
mal to it) that was resolved through aspiration of the debris.
At present, FiberNet® is the only EPD combing distal filtering
with aspiration. While there is no doubt that EPDs should
be routinely used during PCI of degenerated SVG whenever
it is technically feasible [4–8], optimal selection of EPDs for
SVG-PCI should, similarly to carotid artery stenting with EPD
[11, 12], involve choosing the EPD that best suits the target
SVG anatomy and lesion morphology [8].
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Figure 3. Final result of the procedure, after the FiberNet® filter
retrieval
